Aradigm Named to the 2026 New York Digital Health 100 List
Award Recognizes Companies in New York Shaping the Future of Healthcare Innovation
New York, NY (February 3, 2026) – Aradigm, a benefits platform for cell and gene therapies, has been named to the 2026 New York Digital Health 100 List (DH100). This annual recognition is published by Digital Health New York and honors the most innovative, high-impact digital health startups in the New York region.
"We're honored to be recognized among New York's most innovative health companies as we take on one of the defining challenges in healthcare: creating affordable access to lifesaving cell and gene therapies,” said Dr. William Shrank, CEO and Co-Founder of Aradigm. “As we build a novel financial and delivery model to break through cost barriers for these therapies, this award is a testament to the hard work of our dedicated team.”
Now in its seventh year, the DH100 spotlights companies driving healthcare into the future through bold ideas and scalable solutions. Winners for the 2026 list were evaluated based on quantitative and qualitative measures, including leadership presence, number of employees, funding, market fit, differentiated offerings, and community engagement. A full copy of the DHNY 2026 New York Healthcare Innovation Report with all award winners can be found here.
“The breadth and depth of companies named to this year’s DH100 reflect a clear market shift from experimentation to execution,” said Bunny Ellerin, co-founder and CEO of DHNY. “These companies are scaling solutions that improve outcomes while building enduring businesses, demonstrating how innovation at the intersection of care delivery, data, and trust is shaping the next generation of healthcare leaders.”
Cell and gene therapies represent breakthrough treatments and the potential to cure previously incurable diseases, but these therapies carry a steep price tag of up to $4 million. The U.S. healthcare system simply was not built for delivering and paying for these medicines. Aradigm has created a novel financial and delivery model that addresses the challenges facing every stakeholder in the cell and gene therapy ecosystem — payers, providers, manufacturers, and most importantly, patients. The model was developed with a development group including 15 large employers and six leading payers. The company was founded in 2024 and announced a $20 million Series A funding round in December 2025 led by Frist Cressey Ventures with participation from Morgan Health and Andreessen Horowitz.
About Aradigm Health
Aradigm is a benefits platform for cell and gene therapies (CGT) designed to provide sustainable access to life-saving medicines. Aradigm’s novel financial and delivery model addresses the challenges facing every stakeholder — payers, providers, manufacturers, and, most importantly, patients. By creating a large-scale risk pool to cover and pay for all CGT drugs and care, with unspent funds returned, Aradigm can deliver cost predictability for employers and health plans. Aradigm’s end-to-end experience includes a national network of "centers of excellence” and concierge patient support, giving providers volume and rate certainty and patients appropriate, high-quality treatment and outcomes. A public benefit corporation, Aradigm is backed by Frist Cressey, Morgan Health, and Andreessen Horowitz. Learn more at www.aradigmhealth.com.
About Digital Health New York (DHNY)
Digital Health New York (DHNY) is a connected community of digital health leaders who share ideas, spark new directions and create success across the entire ecosystem. As an organization, DHNY seeks to increase the visibility of New York City as a leader in healthcare innovation and showcase the companies and leaders creating the future of healthcare. Its flagship event, DHNY Summit, brings together an elite group of entrepreneurs, investors, payers, providers and executives to cultivate the New York digital health community and drive impactful conversations around the current and future state of digital health. DHNY was founded in 2022 in collaboration with AlleyCorp. For more information or to join DHNY’s mailing list, please visit www.dhny.co.
